The efficacy and safety of JAK inhibitors for atopic dermatitis: a systematic review and meta-analysis

References

• Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360.
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994.
   PubMed Web of Science ®Google Scholar
• Lebwohl M. Psoriasis. Ann Intern Med. 2018;168(7):ITC49–ITC64.
   PubMed Web of Science ®Google Scholar
• Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–390.
   PubMed Web of Science ®Google Scholar
• Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2(1):16082.
   PubMedGoogle Scholar
• Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–1222.
   PubMed Web of Science ®Google Scholar
• Wernham A, Veitch D, Thomas K, et al. What’s new in the treatment and prevention of atopic eczema: a review of systematic reviews published in 2017. Br J Dermatol. 2019;181:54.
   Web of Science ®Google Scholar
• Grey K, Maguiness S. Atopic dermatitis: update for pediatricians. Pediatr Ann. 2016;45(8):e280–e286.
   PubMed Web of Science ®Google Scholar
• Mohan GC, Lio PA. Comparison of dermatology and allergy guidelines for atopic dermatitis management. JAMA Dermatol. 2015;151(9):1009–1013.
   PubMed Web of Science ®Google Scholar
• Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26(8):1045–1060.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132.
   PubMed Web of Science ®Google Scholar
• Kusari A, Han AM, Schairer D, et al. Atopic dermatitis: new developments. Dermatol Clin. 2019;37(1):11–20.
   PubMed Web of Science ®Google Scholar
• Howell MD, Parker ML, Mustelin T, et al. Past, present, and future for biologic intervention in atopic dermatitis. Allergy. 2015;70(8):887–896.
   PubMed Web of Science ®Google Scholar
• Shreberk-Hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: a systematic review. J Am Acad Dermatol. 2017;76(4):745–753.e19.
   PubMed Web of Science ®Google Scholar
• O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012;36(4):542–550.
   PubMed Web of Science ®Google Scholar
• De Medeiros AKA, Speeckaert R, Desmet E, et al. JAK3 as an emerging target for topical treatment of inflammatory skin diseases. PLoS One. 2016;11(10):e0164080.
   PubMed Web of Science ®Google Scholar
• Chang BY, Zhao F, He X, et al. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. J Immunol. 2009;183(3):2183–2192.
   PubMed Web of Science ®Google Scholar
• Klaeschen AS, Wolf D, Brossart P, et al. JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus. Exp Dermatol. 2017;26(8):728–730.
   PubMed Web of Science ®Google Scholar
• Bieber T, Thyssen JP, Reich K, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2021;35(2):476–485.
   PubMed Web of Science ®Google Scholar
• Arora CJ, Khattak FA, Yousafzai MT, et al. The effectiveness of Janus kinase inhibitors in treating atopic dermatitis: a systematic review and meta-analysis. Dermatol Ther. 2020;33(4):e13685.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Thaci D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877–884.
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol. 2020;82(4):823–831.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomised monotherapy phase 3 trials. Br J Dermatol. 2020;183(2):242–255.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.1 (updated September 2020). Cochrane. 2020; [cited 2021 May 31]. Available from: www.training.cochrane.org/handbook.
   Google Scholar
• Li L, Tian J, Tian H, et al. Network meta-analyses could be improved by searching more sources and by involving a librarian. J Clin Epidemiol. 2014;67(9):1001–1007.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Ge L, Tian JH, Li YN, et al. Association between prospective registration and overall reporting and methodological quality of systematic reviews: a meta-epidemiological study. J Clin Epidemiol. 2018;93:45–55.
   PubMed Web of Science ®Google Scholar
• Kehu Y, Xiuxia L, Zhenggang B. Evidence-Based Social Science Method: Systematic Review and Meta-analysis. China: Lanzhou University Press. 2018.
   Google Scholar
• Jia W-Q, Tian J-H, Yang K-H, et al. Open versus laparoscopic pyloromyotomy for pyloric stenosis: a meta-analysis of randomized controlled trials. Eur J Pediatr Surg. 2011;21(2):77–81.
   PubMed Web of Science ®Google Scholar
• Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512–525.
   PubMed Web of Science ®Google Scholar
• Pan B, Ge L, Xun Y-q, et al. Exercise training modalities in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. Int J Behav Nutr Phys Act. 2018;15(1):72.
   PubMedGoogle Scholar
• Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175(5):902–911.
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Nemoto O, Igarashi A, et al. Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study. Br J Dermatol. 2018;178(2):424–432.
   PubMed Web of Science ®Google Scholar
• Bissonnette R. Randomized controlled trial of an oral Janus kinase/spleen tyrosine kinase inhibitor for atopic dermatitis. J Invest Dermatol. 2019;139(11):2251.
   Web of Science ®Google Scholar
• Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2019;80(4):913–921.e9.
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Nemoto O, Igarashi A, et al. Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis. J Allergy Clin Immunol. 2019;144(6):1575–1583.
   PubMed Web of Science ®Google Scholar
• Gooderham MJ, Hong HC, Eshtiaghi P, et al. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78(3 Suppl 1):S28–s36.
   PubMed Web of Science ®Google Scholar
• Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. Jakstat. 2013;2(3):e24137.
   PubMedGoogle Scholar
• Cornelissen C, Lüscher-Firzlaff J, Baron JM, et al. Signaling by IL-31 and functional consequences. Eur J Cell Biol. 2012;91(6–7):552–566.
   PubMed Web of Science ®Google Scholar
• Hong J, Buddenkotte J, Berger TG, et al. Management of itch in atopic dermatitis. Semin Cutan Med Surg. 2011;30(2):71–86.
   PubMed Web of Science ®Google Scholar
• Tian J, Zhang J, Ge L, et al. The methodological and reporting quality of systematic reviews from China and the USA are similar. J Clin Epidemiol. 2017;85:50–58.
   PubMed Web of Science ®Google Scholar
• Yang K. Evidence-based social science: the origin, development and prospects. J Librariansh Inf Sci. 2018;3:1–10.
   Google Scholar
• Yang K, Chen Y, Li Y, et al. Editorial: can China master the guideline challenge? Health Res Policy Syst. 2013;11(1):1.
   PubMedGoogle Scholar